Roche has posted a mixed set of data from two clinical trials of its anti-IL-33/ST2 antibody astegolimab in chronic obstructive pulmonary disease (COPD), casting a shadow over the programme. On the ...
Objective The left atrial stiffness index (LASI) has been proven to be a promising marker for assessing left atrial (LA) and ...
Amgen and AstraZeneca have said their severe asthma therapy Tezspire could have a role to play in chronic obstructive pulmonary disease (COPD) – a key target indication for the drug – despite missing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback